Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of KM-001 in PPKP1 or PC
NCT05435638Phase 1Completed
- Sponsor
- Kamari Pharma
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KM-001 in punctate palmoplantar keratoderma type 1 (PPPK1) and pachyonychia congenita (PC) (2 arms), sponsored by Kamari Pharma. Primary endpoints: Adverse Events at Day 126, Blood and Urine Laboratory Tests at Day 126 and 3 more. Started Jul 2022; status: completed.
02
Drugs
KM-001
03
Conditions
punctate palmoplantar keratoderma type 1 (PPPK1)pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT05435638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435638.